Table 1.
Distribution of demographic and treatment characteristics among survivors of childhood cancer with ongoing follow-up
| Characteristic | Baseline (N=9397)1 N (%) |
Follow-up 1 (FU1) (N=8364) N (%) |
Follow-up 2 (FU2) (N=6951) N (%) |
All 3 questionnaires2 (N=4607) N (%) |
|
|---|---|---|---|---|---|
| Sex | Male | 4997 (53.2) | 4122 (49.3) | 3332 (47.9) | 2201 (47.8) |
| Age at questionnaire | 18–24 years | 3707 (39.4) | 1719 (20.6) | 270 (3.9) | 1725 (37.4) |
| 25–34 years | 4470 (47.6) | 3704 (44.3) | 2700 (38.8) | 2250 (48.8) | |
| 35–44 years | 1196 (12.7) | 2493 (29.8) | 2901 (41.7) | 618 (13.4) | |
| ≥45 years | 24 (0.3) | 448 (5.4) | 1080 (15.5) | 14 (0.3) | |
| Race/Ethnicity | White, not Hispanic | 7870 (84.0) | 7162 (86.0) | 6036 (86.8) | 4023 (87.3) |
| Household income | $60,000+ | 2064 (22.0) | 3146 (37.6) | 3406 (49.0) | 1166 (25.3) |
| $20,000–$59,999 | 4289 (45.6) | 3167 (37.9) | 2266 (32.6) | 2258 (49.0) | |
| < $20,000 | 1857 (19.8) | 887 (10.6) | 635 (9.1) | 758 (16.5) | |
| Not specified | 1187 (12.6) | 1164 (13.9) | 644 (9.3) | 425 (9.2) | |
| Education | College graduate or more | 2792 (29.7) | 3751 (44.8) | 3559 (51.2) | 1796 (39.0) |
| Post high school, some college | 3285 (35.0) | 3099 (37.1) | 1684 (24.2) | 1702 (36.9) | |
| High school graduate or less | 2813 (29.9) | 1460 (17.5) | 759 (10.9) | 926 (20.1) | |
| Not specified | 507 (5.4) | 54 (0.6) | 949 (13.7) | 183 (4.0) | |
| Age at diagnosis | 0–9 years | 4597 (48.9) | 5092 (60.9) | 4160 (59.8) | 2104 (45.7) |
| 10–20 years | 4800 (51.1) | 3272 (39.1) | 2791 (40.2) | 2503 (54.3) | |
| Cancer diagnosis | Leukemia | 2780 (29.6) | 2852 (34.1) | 2396 (34.5) | 1407 (30.5) |
| Central nervous system | 1180 (12.6) | 884 (10.6) | 671 (9.7) | 448 (9.7) | |
| Hodgkin lymphoma | 1670 (17.8) | 1141 (13.6) | 965 (13.9) | 845 (18.3) | |
| NonHodgkin lymphoma | 865 (9.2) | 649 (7.8) | 542 (7.8) | 421 (9.1) | |
| Kidney (Wilms’ tumor) | 611 (6.5) | 790 (9.4) | 647 (9.3) | 290 (6.3) | |
| Neuroblastoma | 372 (4.0) | 549 (6.6) | 478 (6.9) | 174 (3.8) | |
| Soft tissue sarcoma | 902 (9.6) | 762 (9.1) | 637 (9.2) | 479 (10.4) | |
| Bone | 1017 (10.8) | 737 (8.8) | 615 (8.8) | 543 (11.8) | |
| Cranial radiation therapy | Yes | 2559 (27.2) | 2281 (27.3) | 1884 (27.1) | 1283 (27.8) |
| Chest radiation | Yes | 1965 (20.9) | 1581 (18.9) | 1315 (18.9) | 1058 (23.0) |
| Pulmonary-toxic chemo2 | Yes | 3815 (47.1) | 3622 (47.4) | 3072 (47.7) | 2029 (47.6) |
| Anthracyclines | Yes | 3063 (37.8) | 3045 (39.8) | 2590 (40.2) | 1682 (39.4) |
| Number of severe/disabling/life- threatening chronic conditions | 0 | 6514 (69.3) | 5570 (66.6) | 4245 (61.1) | 3144 (68.2) |
| 1 | 2088 (22.2) | 1930 (23.1) | 1708 (24.6) | 1088 (23.6) | |
| 2+ | 795 (8.5) | 864 (10.3) | 998 (14.4) | 375 (8.1) |
1
Excludes participants eligible in Figure 1 who did not report smoking status on the questionnaire: n=19 at Baseline; n= 20 at FU1; n=40 at FU2.
2
Characteristics from the baseline questionnaire
3
Pulmonary-toxic chemotherapy included bleomycin, busulfan, carmustine (BCNU), lomustine (CCNU), or cyclophosphamide